Abu Dhabi Pioneers Collaborative Approach to Responsible AI in Healthcare at Health Leaders Roundtable
ABU DHABI, UAE, April 24, 2025 /PRNewswire/ -- The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the Emirate, convened senior international government officials at the Health Leaders Roundtable to shape a Declaration on AI governance principles for healthcare. Held on the sidelines of Abu Dhabi Global Health Week (ADGHW), it considered the challenges and opportunities in unlocking the potential of artificial intelligence (AI), and explored key principles in the governance of AI in healthcare.
Hosted together with PwC Middle East, findings from the roundtable will inform the development of a collaborative approach that will serve as a reference for governments, health systems, and innovators to ensure that AI's integration into healthcare systems is transparent, responsible, and inclusive.
His Excellency Mansoor Ibrahim Al Mansoori, Chairman of the Department of Health – Abu Dhabi, added: "AI is not tomorrow's technology, it is today's reality. While many of us are adapting to its rise, our children will grow up with it as the norm. That's why the decisions we make today, around ethics, equity, and safety, must be made together. Through this declaration, we will establish a globally accessible guideline that extends beyond borders and commercial interests. This document is a call to action for governments, innovators, and healthcare leaders everywhere."
The forthcoming Declaration on governance principles for AI in healthcare will outline guiding principles for responsible AI deployment to improve health outcomes and protect patient rights. Designed as a globally accessible resource, the declaration will inspire unified governance and serve as a trusted reference for stakeholders worldwide.
In her opening remarks at the Roundtable, Her Excellency Dr. Noura Al Ghaithi, Undersecretary of the Department of Health – Abu Dhabi, stated: "AI has extraordinary potential in healthcare. It is already transforming how we deliver care, how we diagnose, and how we discover. But with great power comes great responsibility. In Abu Dhabi, we are harnessing AI as our engine and policy as our platform, turning data into life-saving insight, and insight into meaningful action. Our vision is to deliver healthcare that is precise, proactive, and personal and to do so in a way that puts people, not technology, at the centre."
During the Roundtable, participants emphasised the need for agile legal and regulatory frameworks to enable the safe and ethical application of AI in healthcare, while enabling innovation. With an emphasis on the need for a human-centred approach, discussions explored key themes including standardisation of data, data privacy and trust, skills development and community engagement.
Key insights from the Roundtable highlight the need for:
The Health Leaders Roundtable brought together a distinguished group of local and international voices, including government officials, AI experts, healthcare executives, and multilateral organisations, to explore the shared principles and practices needed to deploy AI responsibly, effectively, and equitably.
These themes build on Abu Dhabi's rapidly advancing AI ecosystem, which in the field of health, is taking billions of data points, and turning them into life-changing insights.
Supporting the Emirates's approach is the Global AI Healthcare Academy, launched by DoH, which equips healthcare professionals worldwide with theoretical knowledge and hands-on training needed to implement AI technologies effectively, setting a global standard for capacity building. In addition, Malaffi - the region's first Health Information Exchange - provides secure, real-time access to patient data across both public and private healthcare providers. This seamless data integration is crucial for enabling AI tools to be deployed safely, efficiently, and at scale.
ADGHW is a major government initiative from DoH, and serves as a platform for innovation and collaboration under the 2025 theme 'Towards Longevity: Redefining Health and Well-being.' By convening diverse stakeholders from around the world, ADGHW is a community without borders that seeks to advance the future of health and well-being.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
3 hours ago
- Korea Herald
Novogene Establishes New Subsidiary in Korea to Accelerate Multi-Omics Research
SEOUL, South Korea, June 23, 2025 /PRNewswire/ -- Novogene, a global leader in next-generation sequencing (NGS) and multi-omics solutions, today announced the establishment of Novogene Korea Limited, a wholly owned subsidiary headquartered in Seoul. This strategic expansion deepens Novogene's long-standing engagement with Korea's biomedical and biotech sectors, reinforcing its commitment to delivering rapid, high-quality, and cost-effective multi-omics services tailored to local research needs. The new entity provides localized customer support, shorter project timelines, and stronger collaboration with Korea's vibrant scientific community — spanning cancer genomics, microbiome studies, precision medicine, and agricultural genomics. Novogene empowers researchers to accelerate discoveries across genomics, transcriptomics, proteomics, metabolomics, and beyond. "South Korea is a global innovation hub, and by establishing a dedicated team in Seoul, we are investing in the future of multi-omics discovery," said Justin Lee, Vice President, Novogene Asia Pacific, Middle East & Africa (AMEA). "With the launch of Novogene Korea, we are even better positioned to support our customers with rapid, cost-effective, and reliable services that are already trusted by more than 7,300 organizations worldwide. We sincerely thank the Korean scientific community for their continued trust and collaboration in advancing the frontiers of science." Backed by robust government R&D support, world-class academic institutions, and a dynamic biotech ecosystem, South Korea is uniquely positioned to lead the next wave of genomic innovation. Novogene Korea will partner closely with universities, start-ups, and research hospitals to help unlock transformative insights in health, agriculture, and beyond. About Novogene Novogene is a global leader in applying cutting-edge molecular biology technologies and high-performance computing to advance life science and human health research. With one of the world's largest sequencing capacities, Novogene delivers industry-leading multi-omics solutions to academic institutions, clinical researchers, and pharmaceutical companies worldwide. Driven by scientific excellence, trusted service, and uncompromising data quality, Novogene empowers researchers to accelerate discoveries across genomics, transcriptomics, proteomics, metabolomics, and beyond. As a pioneer in multi-omics, Novogene is committed to being your trusted partner in navigating the future of life science innovation.
Korea Herald
3 hours ago
- Korea Herald
EAN Congress: Frequent nightmares triple risk of early death and accelerate ageing, major study finds
HELSINKI, June 23, 2025 /PRNewswire/ -- New research presented today at the European Academy of Neurology (EAN) Congress 2025 reveals that frequent nightmares are associated with significantly accelerated biological ageing and a more than threefold increase in the risk of premature death. This study is the first to show that nightmares independently predict faster biological ageing and earlier mortality – even after accounting for other health issues. Led by Dr Abidemi Otaiku of the UK Dementia Research Institute and Imperial College London, the study analysed data from 2,429 children aged 8 to 10 and 183,012 adults aged 26 to 86 across six long-term population cohorts. Nightmare frequency in adults was self-reported at the start of the study, with participants followed for up to 19 years. For children, nightmare frequency was reported by their parents at the beginning of the study. Results showed that adults reporting weekly nightmares were more than three times as likely to die prematurely (before age 70) compared to those who rarely or never experienced nightmares. Children and adults with more frequent nightmares also exhibited faster biological ageing, which accounted for approximately 40% of the heightened mortality risk. Notably, weekly nightmares were found to be a stronger predictor of premature death than other established risk factors such as smoking, obesity, poor diet, and low physical activity. "Our sleeping brains cannot distinguish dreams from reality", Dr Otaiku explained. "That's why nightmares often wake us up sweating, gasping for breath, and with our hearts pounding – because our fight-or-flight response has been triggered. This stress reaction can be even more intense than anything we experience while awake." He continued, "Nightmares lead to prolonged elevations of cortisol, a stress hormone closely linked to faster cellular ageing. For those who frequently experience nightmares, this cumulative stress may significantly impact the ageing process. Additionally, nightmares disrupt both sleep quality and duration, impairing the body's essential overnight cellular restoration and repair. The combined effects of chronic stress and disrupted sleep likely contribute to the accelerated ageing of our cells and bodies." The association between frequent nightmares and accelerated ageing remained consistent across all ages, sexes, ethnicities, and mental health statuses, indicating a universal effect. Even monthly nightmares were linked to faster ageing and increased mortality compared to rare or no nightmares, emphasising the importance of reducing nightmare frequency across the population.
Korea Herald
8 hours ago
- Korea Herald
KANEKA UBIQUINOL™ WINS COVETED MARKETING AWARD 2025 AT NATURAL HEALTH PRODUCTS NEW ZEALAND SUMMIT
SYDNEY, June 23, 2025 /PRNewswire/ -- Kaneka Corporation Supplement Division APAC, the world-renowned manufacturer and global supplier of Ubiquinol is thrilled to announce that Kaneka Ubiquinol™ has been awarded the prestigious Forbes Packaging Marketing Award 2025 at the Natural Health Products New Zealand (NHPNZ) Summit, further elevating the brand's position and stature in the natural health industry across the APAC region. The win reflects Kaneka Ubiquinol's outstanding efforts in shining the spotlight on the role of mitochondrial health powered by Ubiquinol, in supporting optimal wellbeing. The award celebrates the strategic impact, scientific credibility and executional excellence of its multi-channel marketing programs which have worked to reach, engage and build trust with brandholders, healthcare professionals, pharmacists, media and consumers alike. As a result this has helped position mitochondrial health and Ubiquinol as the new frontier of evidence-based wellbeing. Mitochondria, powered by the naturally occurring antioxidant ubiquinol, are the millions of "powerhouses" found in all cells that generate energy in our body. They are found in the largest concentrations in tissues and organs requiring the highest levels of energy production – heart, brain, liver, lungs, muscles, sperm and ovum. Science shows that from the age of approximately 30 + natural Ubiquinol levels start to decline, which may require supplementation. Kaneka Ubiquinol's unique globally patented precision yeast fermentation process enables the production of bioidentical Ubiquinol, delivering a premium, clinically proven ingredient that supports mitochondrial health. Upon receiving the award Tsuyoshi Takakuwa, Head of Marketing & Sales (APAC) Supplemental Nutrition Business Division, Kaneka Corporation, Japan said "this recognition reflects the collective efforts of our marketing, science, R&D teams, healthcare practitioner partners, brandholders, KOLs and, importantly consumers, united by a shared commitment to science, quality, education and a long-term vision to cement Ubiquinol's role as the foundation of mitochondrial health." On congratulating the team, Kazuki Takita, Oceania & Asia Marketing & Sales Team, Supplement Business Group, Supplement Strategic Unit, added that the award is a powerful testament of the success of the brand's multi-market, multi-channel strategy, which supports Kaneka Ubiquinol's presence and credibility across the APAC region. "This award illustrates our strategic vision: to position Kaneka Ubiquinol™ as a trusted ingredient for healthcare professionals, a premium asset for brandholders, and a clinically supported ingredient for consumers seeking high-quality, evidence-based supplementation to support their overall health and wellbeing," he continued. "Thank you to NHPNZ and the judging panel for this honour and we extend our congratulations to all the other finalists and winners." ABOUT KANEKA UBIQUINOL™ Kaneka Ubiquinol™ is supported by 100+ scientific studies, 80+ patents and 45+ years of research, with applications spanning mitochondrial health, cardiovascular health, cognitive function, women's health, reproductive health, energy production, sleep, stress, healthy ageing and vitality. Kaneka Ubiquinol's impeccable standards are built on the Japanese philosophy of 'Kaizen' meaning 'a commitment to quality, efficiency and pursuit of perfection', from the company's rigorous commitment to quality and research, to their outstanding stakeholder support. Its strict adherence to the highest manufacturing standards guarantees a stable ingredient, free from impurities, meeting rigorous standards and sustainability requirements, setting the global benchmark for production quality. Listed in over 50 countries in 1000+ practitioner and OTC nutraceutical brands since 2006.
